Effects of aerosolized synthetic surfactant, atovaquone, and the combination of these on murine Pneumocystis carinii pneumonia

Journal of Infectious Diseases

Volumn 177, Issue 4, 1998, Pages 1046-1056

  Hughes, Walter T ^a   Sillos, Elaine M ^b   LaFon, Steve ^b   Rogers, Michael ^b   Woolley, Joseph L ^b   Davis, Craig ^b   Studenberg, Scott ^b   Pattishall, Edward ^b   Freeze, Terry ^b   Snyder, Gary ^b   Staton, Scott ^b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; COTRIMOXAZOLE; DEXAMETHASONE; DIPALMITOYLPHOSPHATIDYLCHOLINE; HEXACYCLINE; HEXADECANOL; LUNG SURFACTANT; TETRACYCLINE; TYLOXAPOL;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFECT; ERADICATION THERAPY; INHALATIONAL DRUG ADMINISTRATION; MALE; NEBULIZATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RAT;

EID: 17344362158     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/515252     Document Type: Article

References (12)

1. Walmsley S, Levinton C, Brunton J, et al. A multicenter randomized double-fluid placebo-controlled trial of adjunctive corticosteroids in the treatment of Pneumocystis carinii pneumonia complicating the acquired immune deficiency syndrome. J Acquir Immune Defic Syndr Hum Retrovirol 1995;3:348-57.
2. Kernbaum S, Masliah J, Alcindor LG, Bouton C, Christol D. Phospholipase activities of bronchoalveolar lavage fluid in rat Pneumocystis carinii pneumonia. Br J Exp Pathol 1983;64:75-80.
3. Sheehan PM, Stokes DC, Yeh YY, Hughes WT. Surfactant phospholipids and lavage phospholipase A2 in experimental Pneumocystis carinii pneumonia. Am Rev Respir Dis 1986;134:526-31.
4. Rice WR, Singleton FM, Linke MJ, Walzer PD. Regulation of surfactant phosphatidylcholine secretion from alveolar type cells during Pneumocystis carinii pneumonia in the rat. J Clin Invest 1993;92:2778-82.
5. Eijking EP, van Daal GJ, Tenbrinck R. Effect of surfactant replacement on Pneumocystis carinii pneumonia in rats. Intensive Care Med 1991;17:475-8.
6. Hoffman AGO, Lawrence MG, Ognibene FP, et al. Reduction of pulmonary surfactant in patients with human immunodeficiency virus infection and Pneumocystis carinii pneumonia. Chest 1992;102:1730-6.
7. Escamilla R, Precost MC, Hermant C, Caratero A, Cariven C, Krempf M. Surfactant analysis during Pneumocystis carinii pneumonia in HIV-infected patients. Chest 1992;101:1558-62.
8. Hobar JD, Wright LL, Soll RF, et al. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. J Pediatr 1993;123:757-66.
9. Vermont-Oxford Neonatal Network. A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Pediatrics 1993;97:1-6.
10. Salter AJ, Nichani SH, Macrae D, Wilkinson KA, Novelli V, Tasker RC. Surfactant adjunctive therapy for Pneumocystis carinii pneumonitis in an infant with acute lymphoblastic leukemia. Intensive Care Med 1995;21:261-3.
11. Hughes WT, Gray VL, Gutteridge WE, et al. Efficacy of hydroxynaphthoquinone 566C80 in experimental Pneumocystis carinii pneumonia. Antimicrob Agents Chemother 1990;34:225-8.
12. Hughes W, Leoung G, Kramer F, et al. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med 1993;328:1521-7.